Federal Technology Transfer — Stevenson-Wydler Act & CRADAs

The Stevenson-Wydler Technology Innovation Act of 1980 (15 U.S.C. §§ 3701–3720) — as amended by the Federal Technology Transfer Act of 1986 — established the policy and mechanisms for transferring technology developed in federal laboratories to the private sector for commercial use. The federal government operates over 300 national laboratories — from Los Alamos and Sandia (nuclear weapons) to the National Institutes of Health (biomedical research) to NASA research centers (aerospace) to NIST (measurement science) — employing approximately 170,000 scientists and engineers and spending over $80 billion annually on research. Before Stevenson-Wydler, the inventions and innovations created in these labs largely stayed within the government. (The companion Bayh-Dole Act did the same for universities and small businesses receiving federal research funding.) The Act made technology transfer an explicit mission of every federal laboratory and created the Cooperative Research and Development Agreement (CRADA) — a flexible partnership vehicle that allows federal labs to collaborate directly with private companies, sharing personnel, equipment, and intellectual property to bring government innovations to market.

Current Law (2026)

Legal Authority

• 15 U.S.C. § 3710 — Utilization of federal technology (each federal agency must ensure results of its research are available to the public; labs must actively pursue technology transfer; each lab with 200+ employees must establish an Office of Research and Technology Applications)
• 15 U.S.C. § 3710a — Cooperative Research and Development Agreements (federal lab directors may enter CRADAs with private companies, universities, state/local governments, and other entities; CRADAs allow shared research, personnel exchanges, and IP-sharing arrangements; the lab may agree to keep partner information confidential and grant the partner an exclusive license to resulting inventions)
• 15 U.S.C. § 3710b — Rewards for scientific and engineering personnel (agencies spending $50M+ on lab R&D must create cash award programs for employees who contribute to technology transfer)
• 15 U.S.C. § 3710c — Distribution of royalties (royalties from licensing must be shared with the inventing lab; inventors must receive at least the first $2,000 per year and may receive up to $150,000; remaining funds support the lab's R&D and technology transfer)
• 15 U.S.C. § 3710d — Employee activities (if an agency decides not to patent an employee invention, the employee may request permission to file a patent personally)

How It Works

The workhorse of federal technology transfer is the Cooperative Research and Development Agreement (CRADA) — a partnership between a federal laboratory and one or more non-federal parties (companies, universities, state agencies) to conduct joint research. CRADAs are not procurement; the government doesn't buy anything from the partner. Instead, both sides contribute resources (personnel, equipment, facilities, expertise, funding) to a shared project. The critical incentive: the federal lab can grant the private partner an exclusive or partially exclusive license to any inventions resulting from the CRADA, giving companies a reason to invest in partnerships that might otherwise look like donating R&D to the public. The typical lab-to-market pathway flows through the lab's Office of Research and Technology Applications (ORTA): the lab develops an invention, ORTA evaluates commercial potential, the lab files a patent application, then either licenses the technology to a company or enters a CRADA for further joint development — with royalties flowing back to the lab and the inventor as the product reaches market.

Inventor incentives keep federal scientists engaged in the transfer process: the Act requires royalty income to be shared, with inventors receiving at least the first $2,000 per year and up to $150,000 per year from their invention's royalties; the remainder stays at the lab for further research and technology transfer activities. Cash awards are also available for significant contributions even without patent royalties. An Interagency Working Group on Technology Transfer coordinates policies across the federal R&D enterprise — DOE's Office of Technology Transitions, NIH's Office of Technology Transfer, NASA's Technology Transfer Program, and DOD's transition programs all operate under broadly similar statutory frameworks. Federal labs collectively execute thousands of CRADAs, invention disclosures, and licenses annually; DOE labs alone maintain over 700 active CRADAs and 1,000+ patent licenses; NIH's technology transfer program generates hundreds of millions in royalties annually (largely from foundational biomedical patents). The economic output includes products ranging from GPS technology to cancer treatments to advanced materials — the commercial legacy of federally funded basic research.

How It Affects You

If you're an entrepreneur, startup, or company interested in commercializing federal lab technology: Federal labs are one of the most underutilized sources of licensable intellectual property in the U.S. economy — over $80 billion in annual R&D produces thousands of potentially commercializable inventions, and labs actively seek private sector partners to bring them to market.

Finding the right technology and the right contact is the first challenge. Start with the Federal Laboratory Consortium for Technology Transfer (federallabs.org) — an umbrella organization that connects businesses with federal labs through regional coordinators and a searchable technology database. Agency-specific resources include: DOE's Lab Partnering Service (lps.doe.gov — searchable database of DOE national lab technologies); NIH's iEdison (s-edison.nih.gov — NIH and PHS invention disclosure and patent database); NASA Tech Transfer (technology.nasa.gov — NASA's patent, software, and technology licensing portal). Each lab also has its own Office of Research and Technology Applications (ORTA) — calling the lab's tech transfer office directly is often the most efficient path.

Understanding the two main partnership vehicles: Patent licenses are simpler — you pay royalties to use an existing federal patent in your products. Licenses can be exclusive (only you can use the patent in a defined field and geography), partially exclusive (you plus a limited number of others), or non-exclusive (anyone can license). Exclusive licenses give the strongest commercial position but typically carry higher upfront fees and milestone requirements. CRADAs are more complex partnerships where you and the lab collaborate on new research — you contribute resources (funding, personnel, equipment), the lab contributes its expertise and facilities, and any inventions resulting from the collaboration can be licensed to you under favorable terms. CRADAs are ideal when you need lab expertise to develop your technology further; patent licenses are better when a specific invention already exists and you just need to commercialize it.

Timeline reality: negotiating a CRADA or exclusive license from a federal lab takes 3–18 months depending on the lab, the complexity of the agreement, and whether agency-level approval is required. DOE and NIH have made efforts to standardize CRADA terms; DOD and NASA CRADAs can take longer due to security and export control reviews. If you need a fast path, ask the lab's ORTA about non-exclusive licenses on standard terms — these can often be executed in weeks. Budget for the negotiating delay in your commercialization timeline.

If you're a scientist or engineer at a federal laboratory: Technology transfer is an explicit part of your job description under Stevenson-Wydler — your lab's ORTA exists to help you. When you make an invention, you have an affirmative obligation to disclose it to your ORTA. The process: (1) File an invention disclosure form with your ORTA (each lab has its own form); (2) Your ORTA evaluates the commercial potential and decides whether to file a patent; (3) If the lab declines to file a patent, you may request permission under 15 U.S.C. § 3710d to file the patent in your own name — the agency must decide within 90 days; (4) If a license is ultimately executed on your invention, you receive a minimum of the first $2,000 per year from royalties and up to $150,000 per year, with the remainder supporting the lab's R&D.

For labs spending $50 million or more on R&D annually, cash award programs for technology transfer contributions are required — these recognize scientists who successfully transfer technology to the private sector even when no patent royalties are involved. Ask your ORTA about your lab's specific award program.

Don't underestimate the career value of tech transfer participation. Labs are increasingly evaluated on their technology transfer metrics — invention disclosures, patent applications, licenses executed, CRADAs active, startups formed. Participating makes you valuable to the lab's mission beyond your research output.

If you're an investor or venture capitalist evaluating a startup built on federal lab technology: Lab-spin-out companies can be attractive because the foundational IP is often well-developed (years of federal R&D behind it), patented, and exclusively licensed. But federal lab IP requires due diligence that differs from standard startup IP review:

(1) March-in rights: Under Stevenson-Wydler and the Bayh-Dole Act, the federal government retains march-in rights — the right to require the licensee to grant additional licenses (or grant them itself) if the technology is not being commercialized adequately. March-in has been requested rarely (mostly for pharmaceutical pricing controversies) and never exercised by the government, but it represents a cloud on the exclusivity of your license. Understand the march-in standard in the specific license agreement.

(2) Export control review: Federal lab technologies — especially from DOE, DOD, and NASA labs — may be subject to export controls under EAR or ITAR. If the technology has defense applications, dual-use potential, or was developed in a national security context, confirm the export control classification before planning commercial development involving foreign nationals or foreign customers.

(3) Scope of exclusive license: Federal exclusive patent licenses typically specify a field of use (only this specific commercial application), territory (may be U.S.-only or worldwide), and term (typically the remaining patent term). Understand exactly what exclusivity you have — and what you don't.

(4) Lab collaboration requirements: Many licenses include obligations to continue working with the lab (purchasing equipment, hiring former lab staff, participating in follow-on CRADAs). These can be valuable (ongoing access to lab expertise) or burdensome (unexpected operational constraints). Read the license's commercialization obligations carefully.

State Variations

Technology transfer law is exclusively federal, but:

• State economic development agencies often partner with federal labs to facilitate local technology transfer
• State university-federal lab partnerships combine Bayh-Dole (university patents) and Stevenson-Wydler (lab tech transfer) authorities
• Some states offer tax incentives or grants for companies licensing federal lab technologies
• State-level "innovation hubs" and technology incubators frequently build around federal lab facilities

Implementing Regulations

• 15 CFR Part 404 — Cooperative Research and Development Agreements (CRADAs) and licensing of federally owned inventions (NIST implementation — CRADA terms, intellectual property rights, royalty sharing, partner selection)
• 37 CFR Part 404 — Licensing of government-owned inventions (application, negotiation, terms, revocation of licenses for federally owned patents)
• 48 CFR 27.3 — FAR Subpart 27.3 — Patent rights under government contracts (allocation of rights in inventions, march-in rights, technology transfer clauses)

Pending Legislation

No standalone technology transfer reform bills have been introduced in the 119th Congress. Innovation and commercialization provisions appear in broader R&D legislation — see Federal Research & Development and Bayh-Dole Act.

Recent Developments

The CHIPS and Science Act (2022) included provisions to strengthen federal technology transfer, including funding for NIST's Manufacturing Extension Partnership. The National Science Foundation's new TIP directorate also focuses on translating research to application and support for regional technology hubs near federal labs. Agencies have expanded "lab-embedded entrepreneurship" programs that place entrepreneurs inside federal labs to identify and commercialize technologies. The Department of Energy's "Lab Partnering Service" and similar agency platforms have made it easier for companies to discover and license federal lab technologies online. AI and machine learning tools developed in federal labs are a growing area of technology transfer activity. The interagency group has worked to standardize CRADA terms and reduce the time required to negotiate agreements — historically a barrier to partnerships, as some CRADAs took over a year to finalize.

• DOGE and federal lab staffing (2025): DOGE-driven workforce reductions have hit federal research agencies — DOE national labs, NIH, USDA research stations, NIST. Technology transfer offices within these labs, which manage CRADA negotiations, patent portfolios, and licensing agreements, have been affected by buyouts and RIFs. Labs that rely on Office of Technology Transfer staff to execute industry partnerships are experiencing longer turnaround times. The DOE national lab system (17 labs, ~65,000 employees) has seen significant voluntary departures; some labs have paused CRADA execution pending reorganization.
• CHIPS Act implementation under Trump — NSF TIP at risk: The CHIPS and Science Act's "Science" provisions — including NSF's Technology, Innovation and Partnerships (TIP) directorate — have been reviewed for cuts under the Trump administration. The TIP directorate, funded at ~$880 million annually, drives regional tech hubs and lab-to-market programs that sit at the intersection of Bayh-Dole technology transfer and CHIPS Act industrial policy. Trump's FY2026 budget proposals include significant reductions to NSF, with TIP being a target. Companies in CRADAs and licensing agreements with NSF-funded researchers should monitor TIP program continuity.
• China technology transfer restrictions tightening (2025): The Trump administration has expanded export control restrictions on technology transfer to Chinese entities — including Chinese nationals working in U.S. federal labs. CRADA and licensing agreement reviews for foreign national participation have become more rigorous under Trump. DOE and DOD have issued guidance tightening restrictions on technology transfer activities involving Chinese nationals in sensitive research areas (semiconductors, AI, quantum computing). Federal labs must now screen CRADA partners more carefully for China-nexus risk.